Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
21
WILLF Quote, Financials, Valuation and Earnings
Last price:
$28.97
Seasonality move
:
11.54%
Day range:
$28.97 - $28.97
52-week range:
$28.97 - $43.78
Dividend yield:
0%
P/E ratio:
26.57x
P/S ratio:
1.75x
P/B ratio:
6.36x
Volume:
146
Avg. volume:
184
1-year change:
-22.33%
Market cap:
$6.1B
Revenue:
$3.5B
EPS (TTM):
$1.09
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
WILLF
Demant A/S
|
-- | -- | -- | -- | -- |
|
ASND
Ascendis Pharma A/S
|
$384.3M | $1.18 | 216.8% | -58.02% | $282.67 |
|
BVNRY
Bavarian Nordic A/S
|
-- | -- | -- | -- | -- |
|
GMAB
Genmab A/S
|
$1.1B | $0.28 | 28.02% | -54.13% | $37.94 |
|
ZLDPF
Zealand Pharma A/S
|
$125.6M | -- | 389.61% | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
WILLF
Demant A/S
|
$28.97 | -- | $6.1B | 26.57x | $0.00 | 0% | 1.75x |
|
ASND
Ascendis Pharma A/S
|
$225.00 | $282.67 | $13.8B | -- | $0.00 | 0% | 16.58x |
|
BVNRY
Bavarian Nordic A/S
|
$10.32 | -- | $2.4B | 6.60x | $0.00 | 0% | 2.38x |
|
GMAB
Genmab A/S
|
$29.29 | $37.94 | $18B | 18.92x | $0.00 | 0% | 5.00x |
|
ZLDPF
Zealand Pharma A/S
|
$60.42 | -- | $4.2B | 4.43x | $0.00 | 0% | 3.06x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
WILLF
Demant A/S
|
57.44% | 0.733 | -- | 0.91x |
|
ASND
Ascendis Pharma A/S
|
122.97% | -0.520 | 7.82% | 0.71x |
|
BVNRY
Bavarian Nordic A/S
|
1.01% | 1.561 | 0.75% | 2.34x |
|
GMAB
Genmab A/S
|
48.13% | 0.776 | 28.6% | 1.98x |
|
ZLDPF
Zealand Pharma A/S
|
2.66% | 1.265 | 1.27% | 22.98x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
WILLF
Demant A/S
|
-- | -- | 10.8% | 25.09% | -- | -- |
|
ASND
Ascendis Pharma A/S
|
$256.1M | $11.5M | -33.58% | -880.05% | 4% | $79.2M |
|
BVNRY
Bavarian Nordic A/S
|
$133.4M | $47.5M | 20.59% | 20.81% | 17.31% | $186.7M |
|
GMAB
Genmab A/S
|
$976.3M | $242.8M | 14.51% | 17.69% | 22.97% | $288M |
|
ZLDPF
Zealand Pharma A/S
|
$9.5M | -$79.6M | 49.66% | 51.22% | -740.96% | -$175.8M |
Demant A/S vs. Competitors
-
Which has Higher Returns WILLF or ASND?
Ascendis Pharma A/S has a net margin of -- compared to Demant A/S's net margin of -13.56%. Demant A/S's return on equity of 25.09% beat Ascendis Pharma A/S's return on equity of -880.05%.
Company Gross Margin Earnings Per Share Invested Capital WILLFDemant A/S-- -- $3.1B ASNDAscendis Pharma A/S88.91% -$0.64 $832.6M -
What do Analysts Say About WILLF or ASND?
Demant A/S has a consensus price target of --, signalling downside risk potential of --. On the other hand Ascendis Pharma A/S has an analysts' consensus of $282.67 which suggests that it could grow by 25.48%. Given that Ascendis Pharma A/S has higher upside potential than Demant A/S, analysts believe Ascendis Pharma A/S is more attractive than Demant A/S.
Company Buy Ratings Hold Ratings Sell Ratings WILLFDemant A/S0 0 0 ASNDAscendis Pharma A/S13 0 0 -
Is WILLF or ASND More Risky?
Demant A/S has a beta of 0.589, which suggesting that the stock is 41.114% less volatile than S&P 500. In comparison Ascendis Pharma A/S has a beta of 0.436, suggesting its less volatile than the S&P 500 by 56.356%.
-
Which is a Better Dividend Stock WILLF or ASND?
Demant A/S has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ascendis Pharma A/S offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Demant A/S pays -- of its earnings as a dividend. Ascendis Pharma A/S pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios WILLF or ASND?
Demant A/S quarterly revenues are --, which are smaller than Ascendis Pharma A/S quarterly revenues of $288.1M. Demant A/S's net income of -- is lower than Ascendis Pharma A/S's net income of -$39.1M. Notably, Demant A/S's price-to-earnings ratio is 26.57x while Ascendis Pharma A/S's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Demant A/S is 1.75x versus 16.58x for Ascendis Pharma A/S. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WILLFDemant A/S1.75x 26.57x -- -- ASNDAscendis Pharma A/S16.58x -- $288.1M -$39.1M
-
Which has Higher Returns WILLF or BVNRY?
Bavarian Nordic A/S has a net margin of -- compared to Demant A/S's net margin of 62.31%. Demant A/S's return on equity of 25.09% beat Bavarian Nordic A/S's return on equity of 20.81%.
Company Gross Margin Earnings Per Share Invested Capital WILLFDemant A/S-- -- $3.1B BVNRYBavarian Nordic A/S48.58% $0.73 $2.1B -
What do Analysts Say About WILLF or BVNRY?
Demant A/S has a consensus price target of --, signalling downside risk potential of --. On the other hand Bavarian Nordic A/S has an analysts' consensus of -- which suggests that it could fall by --. Given that Demant A/S has higher upside potential than Bavarian Nordic A/S, analysts believe Demant A/S is more attractive than Bavarian Nordic A/S.
Company Buy Ratings Hold Ratings Sell Ratings WILLFDemant A/S0 0 0 BVNRYBavarian Nordic A/S0 0 0 -
Is WILLF or BVNRY More Risky?
Demant A/S has a beta of 0.589, which suggesting that the stock is 41.114% less volatile than S&P 500. In comparison Bavarian Nordic A/S has a beta of 1.360, suggesting its more volatile than the S&P 500 by 35.968%.
-
Which is a Better Dividend Stock WILLF or BVNRY?
Demant A/S has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bavarian Nordic A/S offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Demant A/S pays -- of its earnings as a dividend. Bavarian Nordic A/S pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios WILLF or BVNRY?
Demant A/S quarterly revenues are --, which are smaller than Bavarian Nordic A/S quarterly revenues of $274.6M. Demant A/S's net income of -- is lower than Bavarian Nordic A/S's net income of $171.1M. Notably, Demant A/S's price-to-earnings ratio is 26.57x while Bavarian Nordic A/S's PE ratio is 6.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Demant A/S is 1.75x versus 2.38x for Bavarian Nordic A/S. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WILLFDemant A/S1.75x 26.57x -- -- BVNRYBavarian Nordic A/S2.38x 6.60x $274.6M $171.1M
-
Which has Higher Returns WILLF or GMAB?
Genmab A/S has a net margin of -- compared to Demant A/S's net margin of 2.93%. Demant A/S's return on equity of 25.09% beat Genmab A/S's return on equity of 17.69%.
Company Gross Margin Earnings Per Share Invested Capital WILLFDemant A/S-- -- $3.1B GMABGenmab A/S92.34% $0.05 $11.3B -
What do Analysts Say About WILLF or GMAB?
Demant A/S has a consensus price target of --, signalling downside risk potential of --. On the other hand Genmab A/S has an analysts' consensus of $37.94 which suggests that it could grow by 29.55%. Given that Genmab A/S has higher upside potential than Demant A/S, analysts believe Genmab A/S is more attractive than Demant A/S.
Company Buy Ratings Hold Ratings Sell Ratings WILLFDemant A/S0 0 0 GMABGenmab A/S6 3 0 -
Is WILLF or GMAB More Risky?
Demant A/S has a beta of 0.589, which suggesting that the stock is 41.114% less volatile than S&P 500. In comparison Genmab A/S has a beta of 0.899, suggesting its less volatile than the S&P 500 by 10.054%.
-
Which is a Better Dividend Stock WILLF or GMAB?
Demant A/S has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Genmab A/S offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Demant A/S pays -- of its earnings as a dividend. Genmab A/S pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios WILLF or GMAB?
Demant A/S quarterly revenues are --, which are smaller than Genmab A/S quarterly revenues of $1.1B. Demant A/S's net income of -- is lower than Genmab A/S's net income of $31M. Notably, Demant A/S's price-to-earnings ratio is 26.57x while Genmab A/S's PE ratio is 18.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Demant A/S is 1.75x versus 5.00x for Genmab A/S. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WILLFDemant A/S1.75x 26.57x -- -- GMABGenmab A/S5.00x 18.92x $1.1B $31M
-
Which has Higher Returns WILLF or ZLDPF?
Zealand Pharma A/S has a net margin of -- compared to Demant A/S's net margin of -550.12%. Demant A/S's return on equity of 25.09% beat Zealand Pharma A/S's return on equity of 51.22%.
Company Gross Margin Earnings Per Share Invested Capital WILLFDemant A/S-- -- $3.1B ZLDPFZealand Pharma A/S88.42% -$0.84 $2.4B -
What do Analysts Say About WILLF or ZLDPF?
Demant A/S has a consensus price target of --, signalling downside risk potential of --. On the other hand Zealand Pharma A/S has an analysts' consensus of -- which suggests that it could fall by -62.76%. Given that Zealand Pharma A/S has higher upside potential than Demant A/S, analysts believe Zealand Pharma A/S is more attractive than Demant A/S.
Company Buy Ratings Hold Ratings Sell Ratings WILLFDemant A/S0 0 0 ZLDPFZealand Pharma A/S0 0 0 -
Is WILLF or ZLDPF More Risky?
Demant A/S has a beta of 0.589, which suggesting that the stock is 41.114% less volatile than S&P 500. In comparison Zealand Pharma A/S has a beta of 0.725, suggesting its less volatile than the S&P 500 by 27.461%.
-
Which is a Better Dividend Stock WILLF or ZLDPF?
Demant A/S has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zealand Pharma A/S offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Demant A/S pays -- of its earnings as a dividend. Zealand Pharma A/S pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios WILLF or ZLDPF?
Demant A/S quarterly revenues are --, which are smaller than Zealand Pharma A/S quarterly revenues of $10.7M. Demant A/S's net income of -- is lower than Zealand Pharma A/S's net income of -$59.1M. Notably, Demant A/S's price-to-earnings ratio is 26.57x while Zealand Pharma A/S's PE ratio is 4.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Demant A/S is 1.75x versus 3.06x for Zealand Pharma A/S. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WILLFDemant A/S1.75x 26.57x -- -- ZLDPFZealand Pharma A/S3.06x 4.43x $10.7M -$59.1M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
77
RNG alert for Feb 21
RingCentral, Inc. [RNG] is up 34.37% over the past day.
Sell
9
FROG alert for Feb 21
JFrog Ltd. [FROG] is down 24.98% over the past day.
Buy
72
SNSE alert for Feb 21
Sensei Biotherapeutics, Inc. [SNSE] is up 23.81% over the past day.
